The apple blood oxygen lawsuit has reshaped how millions of people use their Apple Watch. If you bought one expecting a working blood oxygen sensor, you are not alone in feeling shortchanged.
Apple disabled the SpO2 feature on watches sold in the United States after losing a patent battle with Masimo Corporation. That decision affected every Apple Watch with blood oxygen capability sold since late 2023.
This article covers everything happening in 2026. You will learn which models are affected, who qualifies for compensation, estimated payout ranges, and how to file a claim.
One stat worth knowing right now: Apple has sold over 200 million Apple Watch units globally, and a significant portion of U.S. buyers paid for a feature that no longer works.
What Is the Apple Blood Oxygen Lawsuit?
The apple blood oxygen lawsuit refers to multiple legal battles over the SpO2 sensor in Apple Watch devices. At its core, Masimo Corporation accused Apple of stealing its patented pulse oximetry technology.
This is not one single lawsuit. It is a web of connected legal actions.
The first layer involves Masimo’s patent infringement claims, which led to an International Trade Commission import ban. The second layer involves consumer class action lawsuits filed by Apple Watch buyers who lost a feature they paid for.
| Lawsuit Type | Parties Involved | Core Issue |
|---|---|---|
| Patent Infringement | Masimo vs. Apple | Stolen pulse oximetry technology |
| ITC Import Ban | ITC ruling against Apple | Blocking Watch imports with SpO2 |
| Consumer Class Action | Apple Watch buyers vs. Apple | Lost functionality, misleading marketing |
| Federal Court Patent Case | Masimo vs. Apple (Delaware) | Damages for patent violations |
The patent fight started in 2020 when Masimo filed its first complaint. The consumer lawsuits followed after Apple actually disabled the blood oxygen feature in early 2024.
Both tracks are still active in 2026. They move at different speeds and have different outcomes for different people.
Apple Watch Blood Oxygen Lawsuit 2026: Where Things Stand Now
As of 2026, the apple watch blood oxygen lawsuit sits at a critical turning point. Multiple legal proceedings are running at the same time, and several key decisions are expected this year.
The Federal Circuit upheld the ITC’s import ban in late 2024. Apple attempted a “design-around” by modifying its software algorithms, but Masimo challenged whether those changes actually avoided the patents.
U.S. Customs and Border Protection has been reviewing Apple’s redesigned watches to determine if they still infringe. That review process has stretched into 2026.
On the consumer side, class action lawsuits consolidated in federal court are moving toward certification. Attorneys representing Apple Watch buyers argue the company sold devices with a headline feature it knew might be removed.
- Federal Circuit appeal: Upheld ITC ban, Apple seeking further review
- Customs review: Ongoing evaluation of Apple’s redesigned sensor approach
- Class action status: Moving toward class certification in 2026
- Settlement talks: Informal discussions reported between parties
- Masimo damages trial: Federal court patent damages case still pending
The year 2026 could bring either a settlement announcement or a trial date. Either way, affected consumers should pay attention.
Why Was the Apple Watch Blood Oxygen Feature Removed?
Apple removed the blood oxygen feature because the International Trade Commission ruled that Apple Watch infringed two Masimo patents related to pulse oximetry technology.
The ITC issued a limited exclusion order and a cease-and-desist order in October 2023. These orders banned Apple from importing Apple Watch models containing the infringing blood oxygen sensor technology into the United States.
Apple tried to pause the ban through emergency appeals. The Biden administration declined to veto the ITC order during the 60-day presidential review period, which ended in late December 2023.
Rather than stop selling Apple Watch entirely, Apple chose to disable the blood oxygen app through a software update on new devices sold in the U.S. Existing watch owners kept the feature temporarily, but subsequent software updates in 2024 disabled it for many users.
Think of it like buying a car with heated seats, then getting a software update that turns them off because the car maker lost a patent fight over the heating element. You still have the hardware, but the software won’t let you use it.
Quick Facts:
- Reason for removal: ITC import ban due to patent infringement
- Date of ITC order: October 2023
- Presidential veto: Declined, December 2023
- Method of removal: Software-level disabling of SpO2 app
Key Takeaway: The apple blood oxygen lawsuit involves both a corporate patent war between Apple and Masimo and separate consumer lawsuits from Watch buyers who lost a feature they paid for.
The Masimo Apple Lawsuit Explained
The masimo apple lawsuit began in 2020 when Masimo Corporation filed a complaint with the ITC and a separate federal lawsuit in the Central District of California.
Masimo is a medical technology company based in Irvine, California. It pioneered pulse oximetry technology and holds over 1,000 patents related to blood oxygen monitoring. CEO Joe Kiani publicly accused Apple of hiring away Masimo engineers and using their knowledge to build the Apple Watch SpO2 sensor.
According to Masimo’s ITC complaint (Investigation No. 337-TA-1276), Apple’s blood oxygen sensor infringed at least five Masimo and Cercacor patents. Cercacor is a Masimo subsidiary that developed consumer health monitoring technology.
| Key Detail | Information |
|---|---|
| Plaintiff | Masimo Corporation and Cercacor Laboratories |
| Defendant | Apple Inc. |
| First Filing | June 2020 (ITC) and January 2020 (Federal Court) |
| ITC Investigation Number | 337-TA-1276 |
| Patents at Issue | 5 patents related to pulse oximetry |
| Core Allegation | Apple hired Masimo engineers, stole trade secrets and patented tech |
Apple denied the allegations and filed its own countersuit against Masimo, claiming Masimo’s patents were invalid. Apple also accused Masimo of copying Apple Watch design features in its own W1 smartwatch.
This corporate fight is personal. Both CEOs have made public statements about the dispute, and settlement negotiations have reportedly been difficult.
Understanding the Apple Blood Oxygen Patent Dispute
The apple blood oxygen patent dispute centers on how pulse oximetry works inside a wearable device. At its simplest, the patents cover the way light passes through skin to measure blood oxygen levels.
Pulse oximetry uses light-emitting diodes that shine red and infrared light through your wrist. Sensors on the other side measure how much light passes through. Oxygenated blood absorbs light differently than deoxygenated blood.
Masimo holds patents on specific methods of processing those light signals to produce accurate SpO2 readings. The company argues that Apple’s algorithms and hardware configurations copy these protected methods.
Two patents were central to the ITC ruling:
- U.S. Patent No. 10,912,502: Covers light-based physiological measurement in a wearable device
- U.S. Patent No. 10,945,648: Covers signal processing methods for blood oxygen calculation
Apple’s defense has been multi-pronged. The company challenged the validity of both patents at the Patent Trial and Appeal Board. Apple also argued its technology uses a fundamentally different approach.
In 2025, Apple attempted a “design-around” by modifying its sensor algorithms. Whether that design-around actually avoids Masimo’s patents remains a disputed question in 2026.
The patent dispute is separate from the consumer claims, but its outcome directly affects whether Apple Watch owners ever get the feature back.
Apple Watch Blood Oxygen ITC Ruling: What Happened
The apple watch blood oxygen ITC ruling was a major blow to Apple. In January 2024, the ITC’s final determination found that Apple Watch infringed two Masimo patents, triggering an import ban.
Administrative Law Judge MaryJoan McNamara initially issued a preliminary ruling in January 2023 finding infringement. The full ITC Commission reviewed and largely upheld that finding.
The resulting orders were significant:
| Order Type | What It Does | Effective Date |
|---|---|---|
| Limited Exclusion Order | Bans import of infringing Apple Watch models | January 2024 |
| Cease and Desist Order | Prohibits Apple from selling existing infringing inventory | January 2024 |
| Presidential Review | Biden administration declined to veto | December 2023 |
Apple immediately appealed to the U.S. Court of Appeals for the Federal Circuit. The company won a temporary emergency stay that allowed sales to continue briefly, but the Federal Circuit ultimately upheld the ITC’s decision in late 2024.
The practical result: Apple Watch models with blood oxygen capability cannot be imported into the United States with that feature enabled. Apple responded by disabling the feature rather than halting Watch sales entirely.
This ITC ruling set a precedent. It showed that even the world’s most valuable company is not immune to patent enforcement actions that strip features from consumer products.
Key Takeaway: The ITC ruled against Apple, banning imports of watches with blood oxygen capability, which forced Apple to disable the feature on U.S. devices through software updates.
The Apple Watch Blood Oxygen Ban in the United States
The apple watch blood oxygen ban means every new Apple Watch sold in the U.S. since early 2024 ships without a working blood oxygen sensor. The hardware is physically present inside the watch, but the software blocks it.
This is an unusual situation in consumer electronics. Buyers are paying full price for a device that contains hardware they cannot use.
The ban applies specifically to the U.S. market. Apple Watch units sold in Europe, Asia, and other international markets still have fully functional blood oxygen sensors. If you buy an Apple Watch in London or Tokyo, SpO2 works just fine.
- U.S. buyers pay the same price as international buyers
- The SpO2 hardware sits inside every Apple Watch Series 6 and later
- Only the software prevents the feature from working
- International travelers with U.S. models cannot activate SpO2 abroad
Some Apple Watch owners have expressed frustration on social media, noting they bought their watch specifically for health monitoring. The blood oxygen feature was a major selling point during Apple’s product launches from 2020 through 2023.
Quick Facts:
- Ban scope: United States only
- Hardware present: Yes, in all affected models
- Software disabled: Yes, via watchOS updates
- Price adjustment: None; same retail price
The ban remains in effect in 2026 while legal proceedings continue.
Which Apple Watch Models Are Affected by Blood Oxygen Removal?
The apple watch models affected by blood oxygen removal include every Apple Watch that originally shipped with an SpO2 sensor. That covers models from the Series 6 onward.
Here is a complete list of affected models:
| Model | Release Year | SpO2 Hardware | Feature Status (U.S.) |
|---|---|---|---|
| Apple Watch Series 6 | 2020 | Yes | Disabled via software |
| Apple Watch Series 7 | 2021 | Yes | Disabled via software |
| Apple Watch Series 8 | 2022 | Yes | Disabled via software |
| Apple Watch Series 9 | 2023 | Yes | Disabled at sale / via update |
| Apple Watch Series 10 | 2024 | Yes | Disabled at sale |
| Apple Watch Ultra | 2022 | Yes | Disabled via software |
| Apple Watch Ultra 2 | 2023 | Yes | Disabled at sale / via update |
| Apple Watch SE (all) | Various | No | Not affected (no SpO2 hardware) |
The Apple Watch SE models were never affected because they do not contain the blood oxygen sensor hardware. If you own an SE, this lawsuit does not apply to your device.
For owners of Series 6 through Series 8, the blood oxygen feature worked at purchase but was later disabled through a watchOS software update. Series 9, 10, and Ultra 2 buyers in the U.S. either got the feature briefly or never had it enabled at all.
Millions of units fall into this affected category. Apple has not disclosed exact sales figures by model, but analysts estimate between 50 and 80 million affected devices were sold in the U.S. alone.
How Was the Apple Watch Blood Oxygen Sensor Disabled?
The apple watch blood oxygen sensor was disabled through software, not by physically removing the hardware. Apple pushed watchOS updates that turned off the SpO2 measurement app.
This is an important distinction. The sensor hardware still exists inside your watch. The LEDs, the photodetectors, and the circuitry are all physically present. Apple simply removed the software that interprets the sensor data and displays blood oxygen readings.
When you update to affected versions of watchOS, the Blood Oxygen app disappears from your watch. You can’t find it in settings, and no workaround restores it.
- The green and red LEDs on the back of the watch still function for heart rate
- The infrared LEDs used for SpO2 are powered down by software
- No third-party app can access the raw sensor data for blood oxygen
- Apple locked the SpO2 API so developers cannot build alternatives
Some tech-savvy users attempted to avoid the disabling update by refusing to install new watchOS versions. That works temporarily, but older watchOS versions eventually lose compatibility with newer iPhones and apps.
Apple’s approach has been criticized as a “digital lobotomy.” You paid for a complete device, and a software switch took away one of its key features. This method of compliance with the ITC order is central to the consumer class action arguments.
Can I Get Blood Oxygen Back on My Apple Watch?
Right now, you cannot get blood oxygen back on your Apple Watch if you are in the United States. There is no setting, hack, or workaround that restores the feature on current watchOS versions.
Three scenarios could change this in the future:
Scenario 1: Apple wins the patent dispute. If Apple successfully invalidates Masimo’s patents or wins on appeal, the company could re-enable the feature through a software update. This is the cleanest path but could take years.
Scenario 2: Apple and Masimo reach a licensing deal. If Apple agrees to pay Masimo royalties for using the technology, the feature could return. Settlement talks have been reported, but no deal has been announced as of early 2026.
Scenario 3: Apple’s design-around is approved. If U.S. Customs determines that Apple’s redesigned sensor algorithms do not infringe Masimo’s patents, Apple could re-enable a modified version of blood oxygen monitoring.
| Scenario | Likelihood (2026) | Timeframe |
|---|---|---|
| Patent victory | Low to medium | 2027 or later |
| Licensing deal / settlement | Medium | Possible in 2026 |
| Design-around approval | Medium | Under Customs review now |
Until one of these things happens, the blood oxygen feature stays off for U.S. users. International users are unaffected and continue to use the feature normally.
If you travel abroad, your U.S.-purchased Apple Watch still will not gain SpO2 functionality. The restriction is tied to the software region, not your physical location.
Key Takeaway: There is currently no way to restore blood oxygen on a U.S. Apple Watch, but a settlement, patent win, or approved design-around could bring it back as early as late 2026.
Apple Watch Blood Oxygen Class Action Lawsuits
Multiple apple watch blood oxygen class action lawsuits have been filed by consumers who argue Apple sold them a product with a feature the company knew could be taken away.
These class actions are separate from Masimo’s patent case. They focus on consumer rights, not patent ownership. The core claims include:
- Breach of warranty: Apple sold watches with a blood oxygen feature, then removed it
- Unjust enrichment: Apple charged full price for devices with disabled functionality
- Unfair business practices: Apple marketed SpO2 as a key feature knowing it was at legal risk
- Deceptive advertising: Promotional materials highlighted blood oxygen without disclosing the patent dispute
At least three class action complaints have been filed in federal courts in California and New York. Attorneys from several consumer rights firms are involved.
The proposed class typically includes all persons in the United States who purchased an Apple Watch with blood oxygen functionality between September 2020 and the present.
| Class Action Detail | Information |
|---|---|
| Courts | U.S. District Courts, California and New York |
| Proposed Class | All U.S. buyers of Apple Watch with SpO2 |
| Time Period | September 2020 to present |
| Key Claims | Breach of warranty, unjust enrichment, deceptive marketing |
| Status in 2026 | Moving toward class certification |
Class certification is a major milestone. Once a class is certified, Apple would face potential liability to millions of consumers at once rather than handling individual lawsuits.
Who Is Eligible for the Apple Watch Blood Oxygen Lawsuit?
Eligibility for the apple watch blood oxygen lawsuit generally requires that you purchased an Apple Watch with SpO2 capability in the United States. If you bought a qualifying model, you are likely part of the proposed class.
Specific eligibility criteria vary depending on which class action complaint you look at. But the common requirements across most filings include:
- You purchased an Apple Watch Series 6, 7, 8, 9, 10, Ultra, or Ultra 2
- You bought it in the United States (or a U.S. territory)
- You bought it during the applicable class period (September 2020 onward)
- The blood oxygen feature was either active at purchase and later disabled, or was disabled at the time of purchase
You do not need to show that you personally used the blood oxygen feature every day. The argument is about what you paid for versus what you received.
Proof of purchase strengthens your claim. This includes Apple Store receipts, credit card statements, order confirmation emails, or the device serial number linked to your Apple ID.
| Eligibility Factor | Required? |
|---|---|
| U.S. purchase of qualifying model | Yes |
| Proof of purchase | Recommended but not always required |
| Blood oxygen feature was removed/disabled | Yes |
| Physical harm from missing feature | No (economic harm is sufficient) |
| Apple Care or warranty status | Not relevant |
People who bought refurbished or secondhand Apple Watches may also qualify, though their claims could be evaluated differently. The key question is whether the device originally had blood oxygen capability.
How Much Could the Apple Watch Blood Oxygen Lawsuit Pay Out?
No official payout amounts have been set for the apple watch blood oxygen lawsuit because the cases have not yet reached a settlement or verdict. However, legal analysts and class action attorneys have offered ranges based on similar cases.
In comparable consumer class actions involving disabled features or deceptive marketing, individual payouts have ranged from $25 to $500 per claimant. The exact amount depends on several factors.
| Factor | Impact on Payout |
|---|---|
| Number of claimants | More claimants = smaller individual payments |
| Settlement fund size | Depends on negotiations or jury verdict |
| Purchase price of your Watch | Higher-priced models may receive more |
| Proof of purchase | Could qualify you for a higher payment tier |
| Coupon vs. cash settlement | Cash payments are smaller; coupons may be larger face value |
A realistic estimate for most claimants falls in the $50 to $150 range if the case settles. If it goes to trial and Apple loses, the numbers could be higher.
For context, Apple Watch models retail from $249 to $799. A partial refund representing the “value” of the blood oxygen feature could be calculated as a percentage of the purchase price. Some attorneys argue the SpO2 sensor accounted for 10% to 20% of the product’s marketed value.
One wildcard: if the court grants statutory damages under consumer protection statutes, individual payouts could jump significantly. California’s Unfair Competition Law and Consumer Legal Remedies Act allow for meaningful per-person damages.
Key Takeaway: While no official payouts have been announced, class action attorneys estimate most eligible Apple Watch owners could receive between $50 and $150 in a settlement, with the possibility of more if the case goes to trial.
Apple Watch Blood Oxygen Settlement: Is a Deal Coming?
As of early 2026, no formal apple watch blood oxygen settlement has been announced in the consumer class action cases. However, multiple signs suggest settlement discussions are underway.
On the patent side, Apple and Masimo have engaged in mediation at various points. A patent licensing deal between the two companies could indirectly resolve the consumer claims by restoring the blood oxygen feature.
Settlement negotiations in consumer class actions typically accelerate after class certification. If the court certifies the class in 2026, Apple faces enormous potential liability and has strong financial incentive to settle.
Here is what a settlement might look like based on precedent from similar tech class actions:
| Settlement Component | Possible Form |
|---|---|
| Cash payment per claimant | $50 to $150 |
| Apple Store credit | $75 to $200 per person |
| Feature restoration | Software update re-enabling SpO2 |
| Extended warranty | Additional coverage for affected models |
| Cy pres fund | Donation to health monitoring nonprofits |
The most consumer-friendly outcome would be feature restoration plus a cash payment. But Apple may push for store credit or coupons instead, which is common in tech settlements.
Several legal observers expect at least one significant development on the settlement front by the end of 2026. Whether that is a formal offer, a mediation agreement, or a trial date announcement remains to be seen.
Apple has a track record of settling class actions before trial. The company settled the “Batterygate” iPhone slowdown case for $500 million in 2020, paying $65 per claimant. That case involved similar claims of undisclosed feature degradation.
How to File an Apple Watch Blood Oxygen Claim
Filing an apple watch blood oxygen claim is not yet possible for most consumers because no settlement has been finalized. However, there are steps you can take right now to prepare.
Step 1: Gather your proof of purchase. Find your Apple Store receipt, email confirmation, or credit card statement showing the purchase. Log into your Apple ID account to find your device serial number and purchase date.
Step 2: Check your Apple Watch model. Confirm you own a qualifying model (Series 6 or later with SpO2 hardware). The Apple Watch SE does not qualify.
Step 3: Document the disabled feature. Take a screenshot showing the Blood Oxygen app is missing from your watch. Note the watchOS version that disabled it.
Step 4: Register with a class action firm. Several law firms handling these cases allow you to register your interest on their websites. This does not commit you to anything, but it ensures you receive notifications when claims open.
Step 5: Wait for the claims process to open. Once a settlement is approved or a verdict is reached, a claims administrator will create a formal process. You will submit your information and proof.
| Preparation Step | What You Need |
|---|---|
| Proof of purchase | Receipt, email, credit card statement |
| Device information | Serial number, model, purchase date |
| Feature documentation | Screenshot of missing Blood Oxygen app |
| Registration | Sign up with a handling law firm |
| Patience | Claims process not yet open |
Do not pay anyone to file a claim on your behalf. Legitimate class action claims are free to submit. Any service charging you a fee is likely a scam.
The Apple Watch Pulse Oximeter Lawsuit: Technical Details
The apple watch pulse oximeter lawsuit hinges on specific technical claims about how Apple’s sensor measures blood oxygen saturation. Understanding the technology helps explain why this case is so complex.
Pulse oximetry measures SpO2 (peripheral blood oxygen saturation) by shining light through tissue and measuring absorption differences. Traditional medical pulse oximeters clip onto your fingertip. Apple adapted this technology for a wrist-worn device.
Masimo’s patents cover specific innovations that made wrist-based pulse oximetry more accurate:
- Motion artifact rejection: Filtering out noise caused by wrist movement
- Adaptive signal processing: Adjusting measurements based on skin tone and blood flow
- Multi-wavelength light analysis: Using multiple LED colors for better accuracy
- Low-perfusion measurement: Getting readings even when blood flow is weak
Apple’s SpO2 sensor uses green, red, and infrared LEDs on the back crystal of the watch. The company developed custom algorithms to process these signals. Masimo argues those algorithms are covered by its patents.
The technical complexity matters because Apple’s “design-around” defense depends on proving its modified algorithms work differently enough to avoid the patents. Patent experts disagree on whether Apple’s changes are substantive or cosmetic.
In medical settings, Masimo pulse oximeters are used in hospitals worldwide. The company generates over $2 billion in annual revenue from its medical devices. Apple’s entry into consumer pulse oximetry threatened Masimo’s potential expansion into the consumer wearable market.
Key Takeaway: The technical dispute centers on whether Apple’s sensor algorithms copy Masimo’s patented methods for measuring blood oxygen through the wrist, and Apple’s attempt to redesign around those patents is still being evaluated in 2026.
Apple Watch Blood Oxygen Feature Timeline: Key Dates
The apple watch blood oxygen feature timeline spans six years of development, legal battles, and consumer impact. Here is every major date that matters.
| Date | Event |
|---|---|
| September 2020 | Apple Watch Series 6 launches with SpO2 sensor |
| January 2020 | Masimo files patent infringement lawsuit in federal court |
| June 2020 | Masimo files ITC complaint (337-TA-1276) |
| January 2023 | ITC ALJ issues initial determination finding infringement |
| October 2023 | ITC issues final exclusion order and cease-and-desist |
| December 2023 | Biden administration declines presidential veto of ITC order |
| January 2024 | Apple Watch import ban takes effect |
| January 2024 | Apple begins disabling SpO2 on new U.S. devices |
| Mid-2024 | Software updates disable SpO2 on older models for many users |
| Late 2024 | Federal Circuit upholds ITC ruling on appeal |
| Early 2025 | Apple submits “design-around” to U.S. Customs for review |
| Mid-2025 | Consumer class action complaints filed in California and New York |
| Late 2025 | Class action cases consolidated; discovery begins |
| Early 2026 | Class certification motions filed |
| 2026 (expected) | Customs decision on design-around; possible settlement talks |
This timeline shows the dispute accelerating. What started as a corporate patent fight in 2020 has become a full-blown consumer rights issue by 2026.
The next 12 months are likely the most consequential. Multiple legal decisions are expected, and each one could change the trajectory for millions of Apple Watch owners.
Three dates to watch closely in 2026: the Customs ruling on Apple’s design-around, the class certification hearing, and any scheduled mediation or settlement conference.
Early adopters who bought the Series 6 in September 2020 have now gone over a year without the blood oxygen feature. They paid $399 or more for a watch that was marketed heavily around health monitoring capabilities that no longer work.
Frequently Asked Questions
Is there a class action lawsuit for Apple Watch blood oxygen removal?
Yes, multiple class action lawsuits have been filed against Apple by consumers who lost the blood oxygen feature.
These cases are pending in federal courts in California and New York.
They are moving toward class certification in 2026.
How much money can I get from the Apple blood oxygen lawsuit?
Most legal analysts estimate individual payouts between $50 and $150 if the case settles.
The exact amount depends on the settlement fund size and number of claimants.
Higher payouts are possible if the case goes to trial.
Which Apple Watch models lost the blood oxygen feature?
The Apple Watch Series 6, 7, 8, 9, 10, Ultra, and Ultra 2 all had blood oxygen capability.
All of these models have had the SpO2 feature disabled in the United States.
The Apple Watch SE is not affected because it never had an SpO2 sensor.
Will Apple restore the blood oxygen feature on existing watches?
Apple could restore the feature through a software update if it wins the patent dispute, reaches a licensing deal with Masimo, or gets its design-around approved by Customs.
No restoration has happened yet as of early 2026.
A settlement between Apple and Masimo is the most likely path to getting the feature back.
What is the deadline to file an Apple Watch blood oxygen claim?
No filing deadline has been set because no settlement has been finalized yet.
Once a settlement is approved, a claims window will open with a specific deadline.
You can register with class action law firms now to receive notifications when the process begins.
This lawsuit is far from over. The year 2026 is shaping up to be the most important yet for Apple Watch owners waiting for answers on the blood oxygen dispute.
Gather your proof of purchase now. Document your disabled feature. Register your interest with a law firm handling the case.
When the claims window opens, you will want to be ready. Your Apple Watch has the sensor inside it. Whether the software ever turns it back on depends on what happens in courtrooms this year.
